Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM56YN7)

• Drug Name: Desloratadine Drug Info
• Synonyms: Aerius; Allex; Azomyr; Claramax; Clarinex; Denosin; Desalex; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratidine; Neoclarityn; Opulis; Clarinex RediTabs; Desloratadine [USAN]; Essex brand of desloratadine; Schering brand of desloratadine; Sch 34117; Aerius (TN); Claramax (TN); Clarinex (TN); NeoClarityn (TN); Sch-34117; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
• Therapeutic Class: Antiallergic Agents
• Cross-matching ID:
  PubChem CID: 124087
  ChEBI ID: CHEMBL1172
  CAS Number: CAS 100643-71-8
  TTD Drug ID: D01GBY
  VARIDT Drug ID: DR00497
  INTEDE Drug ID: DR1761
  ACDINA Drug ID: D00180

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Intestinal immune network for IgA production	2.08	1.05e-2	38/48 (79.17%)	CXCL12;HLA-DMB;HLA-DPA1;...
Viral protein interaction with cytokine and cytokine re...	2.00	5.24e-3	84/100 (84%)	CXCL14;CCL19;CCL8;...
Phagosome	1.98	6.98e-3	118/152 (77.63%)	CYBB;CYBA;C1R;...
Leishmaniasis	1.91	7.86e-3	67/77 (87.01%)	CYBB;CYBA;MARCKSL1;...
Rheumatoid arthritis	1.90	6.28e-3	78/93 (83.87%)	CXCL12;HLA-DMB;HLA-DPA1;...
Allograft rejection	1.90	5.24e-3	32/38 (84.21%)	HLA-DMB;HLA-DPA1;CD40;...
Systemic lupus erythematosus	1.85	1.05e-2	45/135 (33.33%)	C1S;C1R;C1QA;...
Primary immunodeficiency	1.79	2.49e-2	33/38 (86.84%)	LCK;CD79A;CD40;...
Autophagy	1.79	2.68e-2	113/169 (66.86%)	BAD;DDIT4;KRAS;...
Hematopoietic cell lineage	1.79	2.41e-2	90/99 (90.91%)	IL7;MME;HLA-DMB;...
Staphylococcus aureus infection	1.77	2.67e-2	72/95 (75.79%)	C1S;C1R;KRT19;...
Lysosome	1.74	3.23e-2	115/128 (89.84%)	CTSH;ACP5;CTSA;...
Graft-versus-host disease	1.70	5.00e-2	32/42 (76.19%)	HLA-DMB;HLA-DPA1;HLA-DOB;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H	Show ▼

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼